Gut Microbiota Modulation in Chronic Kidney Disease

Chronic kidney disease (CKD) is increasingly recognised as a multisystem disorder in which alterations of the gut microbial community contribute to disease progression and systemic complications. Dysbiosis, characterised by a reduction in beneficial anaerobic bacteria and an overgrowth of pathobionts, fosters intestinal barrier dysfunction, endotoxin translocation and the accumulation of protein-bound uremic toxins. These toxins, including indoxyl sulfate and p-cresyl sulfate, exacerbate oxidative stress, inflammation and cardiovascular risk in CKD patients. Interventions aimed at restoring microbial balance—such as dietary fibre enrichment, prebiotic and probiotic administration—have been shown to increase short-chain fatty acid production, reinforce epithelial integrity and reduce toxin generation. Advances in high-throughput sequencing and metabolomics have illuminated the complex interplay between microbial taxa, metabolic pathways and clinical parameters, laying the groundwork for personalised microbiota-targeted therapies to slow CKD progression and improve patient outcomes.

Research from Nature Portfolio

A foundational study in a Chinese cohort of end-stage renal disease patients revealed marked shifts in gut community structure, with a switch from Prevotella-dominated to Bacteroides-dominated enterotypes. Beneficial butyrate producers—such as Roseburia and Faecalibacterium—were significantly depleted, while pro-inflammatory taxa expanded. Multivariate analyses identified renal function markers (cystatin C, creatinine and estimated glomerular filtration rate) as key drivers of community composition. Quantitative assessments showed that reductions in specific bacterial groups correlated with elevated C-reactive protein and other indices of systemic inflammation. These findings underscore the bidirectional relationship between renal impairment and gut ecology and highlight microbial taxa as potential biomarkers and therapeutic targets in CKD.

Gut Microbiota Modulation in Chronic Kidney Disease publication trend

The graph below shows the total number of articles in gut microbiota modulation in chronic kidney disease across all publications each year (not limited to Nature Index journals).

Technical terms

Gut microbiota: The community of bacteria, archaea, viruses and fungi residing in the gastrointestinal tract.

Dysbiosis: A harmful imbalance in microbial composition and function.

Uremic toxins: Metabolites retained in the circulation due to impaired renal clearance, many of which are produced or modified by gut microbes.

Metagenomics: The study of genetic material recovered directly from environmental samples, enabling characterisation of microbial communities without culturing.

Estimated glomerular filtration rate (eGFR): A calculated measure of kidney filtration function, commonly used to assess CKD stage.

References

1. p-Cresyl Sulfate. Toxins (2017).
2. The Impact of CKD on Uremic Toxins and Gut Microbiota. Toxins (2021).
3. High Amylose Resistant Starch Diet Ameliorates Oxidative Stress, Inflammation, and Progression of Chronic Kidney Disease. PLOS ONE (2014).
4. Randomized Controlled Trial of Strain‐Specific Probiotic Formulation (Renadyl) in Dialysis Patients. BioMed Research International (2014).
5. Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease. Journal of Translational Medicine (2019).
6. Alteration of the gut microbiota in Chinese population with chronic kidney disease. Scientific Reports (2017).
7. Perturbed gut microbiome and fecal and serum metabolomes are associated with chronic kidney disease severity. Microbiome (2023).
8. Metagenome-wide analysis uncovers gut microbial signatures and implicates taxon-specific functions in end-stage renal disease. Genome Biology (2023).
9. Association of the gut microbiome with kidney function and damage in the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Gut Microbes (2023).
10. Gut-Microbiota-Metabolite Axis in Early Renal Function Decline. PLOS ONE (2015).